BridgeBio Pharma (BBIO) Financials

$34.24 -0.61 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$35.05 +0.81 (+2.37%)

As of 07:42 PM Eastern

Annual Income Statements for BridgeBio Pharma

This table shows BridgeBio Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-31	-131	-261	-449	-563	-481	-643	-536
Consolidated Net Income / (Loss)	-44	-169	-289	-505	-586	-485	-653	-543
Net Income / (Loss) Continuing Operations	-44	-169	-289	-505	-586	-485	-653	-543
Total Pre-Tax Income	-44	-169	-289	-505	-586	-485	-653	-542
Total Operating Income	-44	-184	-266	-474	-577	-512	-607	-593
Total Gross Profit	0.00	0.00	41	8.25	67	74	6.86	218
Total Revenue	0.00	0.00	41	8.25	70	78	9.30	222
Operating Revenue	0.00	0.00	41	8.25	70	78	9.30	222
Total Cost of Revenue	0.00	0.00	0.00	0.00	3.11	3.43	2.45	3.88
Operating Cost of Revenue	-	-	0.00	-	3.11	3.43	2.45	3.88
Total Operating Expenses	44	184	307	483	643	586	614	811
Selling, General & Admin Expense	13	44	94	146	192	143	151	289
Research & Development Expense	31	140	210	337	451	399	456	506
Restructuring Charge	-	-	-	0.00	0.00	44	7.93	16
Total Other Income / (Expense), net	0.03	14	-22	-31	-9.82	28	-46	51
Interest Expense	0.01	2.55	8.77	37	47	80	81	126
Interest & Investment Income	0.04	21	-12	4.02	1.13	7.54	18	164
Other Income / (Expense), net	0.00	-4.30	-1.63	1.63	36	100	17	12
Income Tax Expense	-	-	-	-	-	0.00	0.00	1.15
Net Income / (Loss) Attributable to Noncontrolling Interest	-13	-39	-28	-57	-24	-3.47	-10	-7.59
Basic Earnings per Share	($1.00)	($2.12)	($2.48)	($3.80)	($3.90)	($3.26)	($3.95)	($2.88)
Weighted Average Basic Shares Outstanding	30.60M	61.77M	105.10M	118.00M	144.36M	147.47M	162.79M	186.08M
Diluted Earnings per Share	($1.00)	($2.12)	($2.48)	($3.80)	($3.90)	($3.26)	($3.95)	($2.88)
Weighted Average Diluted Shares Outstanding	30.60M	61.77M	105.10M	118.00M	144.36M	147.47M	162.79M	186.08M
Weighted Average Basic & Diluted Shares Outstanding	30.60M	61.77M	105.10M	118.00M	144.36M	151.37M	175.83M	190.19M

This table shows BridgeBio Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-137	-138	-140	-158	-177	-168	-35	-73	-162	-265
Consolidated Net Income / (Loss)	-140	-141	-143	-161	-179	-170	-36	-76	-164	-267
Net Income / (Loss) Continuing Operations	-140	-141	-143	-161	-179	-170	-36	-76	-164	-267
Total Pre-Tax Income	-140	-141	-143	-161	-179	-170	-36	-76	-164	-266
Total Operating Income	-129	-129	-126	-146	-158	-177	0.34	-176	-192	-226
Total Gross Profit	-0.40	-0.13	1.18	1.04	3.49	1.15	211	1.57	2.13	3.80
Total Revenue	0.34	1.87	1.83	1.64	4.09	1.75	211	2.17	2.73	5.88
Operating Revenue	0.34	1.87	1.83	1.64	4.09	1.75	211	2.17	2.73	5.88
Total Cost of Revenue	0.74	2.00	0.65	0.60	0.60	0.60	0.60	0.60	0.60	2.08
Operating Cost of Revenue	0.74	-	0.65	0.60	0.60	0.60	0.60	0.60	0.60	2.08
Total Operating Expenses	129	130	127	147	161	179	210	177	194	230
Selling, General & Admin Expense	31	32	31	36	36	48	66	60	69	95
Research & Development Expense	93	91	93	107	125	130	141	115	120	130
Restructuring Charge	5.02	7.69	3.37	3.53	0.27	0.75	3.40	2.89	4.62	4.69
Total Other Income / (Expense), net	-11	-11	-17	-15	-22	7.09	-37	100	27	-40
Interest Expense	20	20	20	21	20	20	50	23	23	30
Interest & Investment Income	2.42	4.09	4.15	4.51	3.79	5.58	4.08	124	49	-12
Other Income / (Expense), net	6.33	4.56	-0.60	1.48	-5.28	22	9.48	-0.63	1.80	1.62
Net Income / (Loss) Attributable to Noncontrolling Interest	-2.85	-2.98	-2.58	-2.80	-2.49	-2.18	-0.94	-2.09	-2.21	-2.34
Basic Earnings per Share	($0.93)	($0.91)	($0.92)	($0.98)	($1.08)	($0.97)	($0.20)	($0.39)	($0.86)	($1.43)
Weighted Average Basic Shares Outstanding	147.94M	147.47M	152.65M	160.54M	163.31M	162.79M	178.71M	187.59M	188.51M	186.08M
Diluted Earnings per Share	($0.93)	($0.91)	($0.92)	($0.98)	($1.08)	($0.97)	($0.20)	($0.39)	($0.86)	($1.43)
Weighted Average Diluted Shares Outstanding	147.94M	147.47M	152.65M	160.54M	163.31M	162.79M	178.71M	187.59M	188.51M	186.08M
Weighted Average Basic & Diluted Shares Outstanding	149.48M	151.37M	160.50M	162.47M	173.97M	175.83M	187.13M	188.03M	188.99M	190.19M

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	72	344	-72	-5.52	38	21	-22	289
Net Cash From Operating Activities	-40	-137	-254	-400	-498	-419	-528	-521
Net Cash From Continuing Operating Activities	-40	-137	-254	-400	-498	-419	-528	-521
Net Income / (Loss) Continuing Operations	-44	-169	-289	-505	-586	-485	-653	-543
Consolidated Net Income / (Loss)	-44	-169	-289	-505	-586	-485	-653	-543
Depreciation Expense	-	-	0.86	1.46	5.84	6.77	6.49	6.08
Non-Cash Adjustments To Reconcile Net Income	2.10	10	45	86	61	30	114	-15
Changes in Operating Assets and Liabilities, net	1.24	22	-11	18	21	28	5.06	32
Net Cash From Investing Activities	-0.46	-21	-217	-53	-201	453	54	61
Net Cash From Continuing Investing Activities	-0.46	-21	-217	-53	-201	453	54	61
Purchase of Property, Plant & Equipment	-0.46	-2.18	-2.64	-7.52	-13	-4.82	-1.31	-0.93
Acquisitions	0.00	-16	0.00	0.00	-35	-1.50	0.00	-7.98
Purchase of Investments	0.00	0.00	-213	-288	-643	-193	-137	-114
Sale of Property, Plant & Equipment	-	0.00	-	0.00	0.00	10	0.00	0.00
Sale and/or Maturity of Investments	-	0.00	0.00	249	477	533	193	184
Other Investing Activities, net	-	0.00	-1.72	-6.76	14	110	-0.50	-0.14
Net Cash From Financing Activities	113	502	399	447	736	-13	452	748
Net Cash From Continuing Financing Activities	113	502	397	447	733	-13	452	748
Repayment of Debt	0.13	55	-0.82	-13	-140	-20	0.00	-489
Issuance of Debt	4.00	1.00	37	550	1,204	0.00	0.00	450
Issuance of Common Equity	0.00	96	391	25	3.82	7.41	453	319
Other Financing Activities, net	2.98	59	25	-35	-49	-0.90	-1.67	469
Cash Interest Paid	0.00	1.57	6.09	15	30	54	61	91

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	13	-69	18	-110	199	-129	83	72	-142	275
Net Cash From Operating Activities	-135	-93	-144	-113	-145	-125	-220	75	-181	-195
Net Cash From Continuing Operating Activities	-135	-93	-144	-113	-145	-125	-220	75	-181	-195
Net Income / (Loss) Continuing Operations	-140	-141	-143	-161	-179	-170	-36	-76	-164	-267
Consolidated Net Income / (Loss)	-140	-141	-143	-161	-179	-170	-36	-76	-164	-267
Depreciation Expense	1.65	1.66	1.63	1.64	1.64	1.59	1.60	1.57	1.54	1.37
Non-Cash Adjustments To Reconcile Net Income	4.96	40	35	34	35	10	-194	137	-16	56
Changes in Operating Assets and Liabilities, net	-1.58	6.10	-38	11	-2.13	34	8.54	12	-2.32	14
Net Cash From Investing Activities	147	18	12	4.12	38	-0.07	23	3.04	38	-3.24
Net Cash From Continuing Investing Activities	147	18	12	4.12	38	-0.07	23	3.04	38	-3.24
Purchase of Property, Plant & Equipment	-0.76	-0.80	-0.01	-0.43	-0.43	-0.44	-0.70	-0.05	-0.14	-0.05
Acquisitions	-	-	0.00	-	-	-	-0.80	-2.39	-1.60	-3.19
Net Cash From Financing Activities	1.45	6.38	150	-1.23	307	-4.52	280	-5.73	0.71	474
Net Cash From Continuing Financing Activities	1.45	6.38	150	-1.23	307	-4.52	280	-5.73	0.71	474
Other Financing Activities, net	-0.15	-0.43	-0.32	-1.08	3.80	-4.07	-2.40	-1.50	-1.41	474
Cash Interest Paid	22	6.87	22	6.68	22	10	35	14	29	13

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Total Assets	465	632	704	1,013	623	546	919
Total Current Assets	445	569	643	889	549	478	721
Cash & Equivalents	436	364	356	394	377	376	681
Restricted Cash	-	-	-	0.18	38	17	0.13
Short-Term Investments	0.00	182	251	443	95	59	0.00
Note & Lease Receivable	-	-	-	20	17	0.00	0.00
Accounts Receivable	-	2.85	-	-	-	1.75	4.72
Prepaid Expenses	9.14	20	36	32	22	24	35
Plant, Property, & Equipment, net	1.58	5.63	20	30	15	12	7.01
Total Noncurrent Assets	18	57	40	94	60	57	192
Long-Term Investments	17	31	-	-	-	0.00	144
Intangible Assets	-	-	0.00	45	29	26	24
Other Noncurrent Operating Assets	1.09	26	40	49	31	31	24
Total Liabilities & Shareholders' Equity	465	632	704	1,013	623	546	919
Total Liabilities	88	156	596	1,878	1,868	1,889	2,377
Total Current Liabilities	33	60	96	135	121	144	154
Accounts Payable	14	8.85	8.95	12	12	11	9.62
Accrued Expenses	12	26	46	81	67	66	67
Current Deferred Revenue	-	-	-	0.00	8.16	6.10	15
Current Employee Benefit Liabilities	4.05	13	30	37	31	57	58
Other Current Liabilities	3.01	12	9.35	4.94	3.68	4.13	4.51
Total Noncurrent Liabilities	55	95	500	1,743	1,747	1,745	2,223
Long-Term Debt	55	92	92	431	431	446	437
Noncurrent Deferred Revenue	-	-	-	-	-	3.73	17
Other Noncurrent Operating Liabilities	0.50	3.53	408	1,313	1,316	1,295	1,768
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.12	2.24	1.63	1.42	-1.59	0.48	0.14
Total Equity & Noncontrolling Interests	377	474	106	-867	-1,243	-1,343	-1,458
Total Preferred & Common Equity	315	408	58	-870	-1,255	-1,354	-1,468
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	315	408	58	-870	-1,255	-1,354	-1,468
Common Stock	494	848	1,021	842	939	1,481	1,903
Retained Earnings	-179	-440	-889	-1,437	-1,918	-2,561	-3,096
Treasury Stock	-	0.00	-75	-275	-275	-275	-275
Accumulated Other Comprehensive Income / (Loss)	0.00	0.25	0.19	-0.13	-0.33	0.03	0.01
Noncontrolling Interest	62	65	48	3.41	11	11	10

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	729	626	504	655	849	794	665
Total Current Assets	642	553	433	588	783	616	445
Cash & Equivalents	483	407	302	505	475	408	266
Restricted Cash	-	26	20	17	0.13	139	139
Short-Term Investments	109	84	81	38	44	40	0.00
Note & Lease Receivable	25	11	8.61	5.17	235	0.66	0.48
Prepaid Expenses	26	25	21	23	28	28	38
Plant, Property, & Equipment, net	16	14	13	12	11	9.84	8.70
Total Noncurrent Assets	71	59	58	55	54	168	212
Long-Term Investments	-	-	-	-	-	117	160
Intangible Assets	29	28	28	27	26	25	25
Other Noncurrent Operating Assets	42	31	30	28	29	26	27
Total Liabilities & Shareholders' Equity	729	626	504	655	849	794	665
Total Liabilities	1,859	1,839	1,853	1,849	1,886	1,876	1,883
Total Current Liabilities	119	97	110	106	141	134	139
Accounts Payable	10	4.08	3.87	4.47	4.73	18	13
Accrued Expenses	73	63	68	57	86	67	66
Current Deferred Revenue	7.52	6.68	6.21	6.59	14	15	12
Current Employee Benefit Liabilities	25	19	29	34	32	29	44
Other Current Liabilities	4.04	3.67	3.78	4.14	4.54	4.62	4.60
Total Noncurrent Liabilities	1,740	1,743	1,743	1,743	1,745	1,742	1,744
Long-Term Debt	1,699	436	440	442	435	435	436
Noncurrent Deferred Revenue	-	-	-	-	20	17	19
Other Noncurrent Operating Liabilities	41	1,307	1,303	1,301	1,290	1,290	1,289
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-2.39	-0.20	0.33	1.40	0.53	-0.22	0.65
Total Equity & Noncontrolling Interests	-1,128	-1,213	-1,350	-1,195	-1,037	-1,082	-1,219
Total Preferred & Common Equity	-1,138	-1,226	-1,362	-1,208	-1,050	-1,093	-1,230
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-1,138	-1,226	-1,362	-1,208	-1,050	-1,093	-1,230
Common Stock	917	1,107	1,128	1,460	1,821	1,851	1,876
Retained Earnings	-1,781	-2,057	-2,215	-2,392	-2,596	-2,669	-2,831
Treasury Stock	-275	-275	-275	-275	-275	-275	-275
Accumulated Other Comprehensive Income / (Loss)	-0.35	-0.01	0.06	0.03	0.00	-0.00	0.01
Noncontrolling Interest	10	12	12	12	12	11	11

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	-79.66%	745.14%	11.38%	-88.02%	2,285.27%
EBITDA Growth	0.00%	-328.56%	-42.06%	-76.55%	-13.49%	24.30%	-44.08%	1.52%
EBIT Growth	0.00%	-328.56%	-42.51%	-76.52%	-14.37%	23.86%	-43.29%	1.58%
NOPAT Growth	0.00%	-318.76%	-44.96%	-78.22%	-21.53%	11.17%	-18.58%	2.37%
Net Income Growth	0.00%	-286.59%	-70.31%	-75.16%	-16.02%	17.36%	-34.79%	16.82%
EPS Growth	0.00%	-112.00%	-16.98%	-53.23%	-2.63%	16.41%	-21.17%	27.09%
Operating Cash Flow Growth	0.00%	-237.49%	-85.58%	-57.62%	-24.57%	15.75%	-25.80%	1.33%
Free Cash Flow Firm Growth	0.00%	0.00%	-84.78%	132.19%	625.00%	-166.23%	-30.97%	120.57%
Invested Capital Growth	0.00%	0.00%	55.94%	-4,225.81%	-213.74%	-4.10%	-1.80%	-36.93%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-62.41%	22.41%	-12.42%	-1.33%	1.90%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-10.36%	-2.24%	3.06%	-5.62%	-13.64%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-10.70%	-2.43%	2.98%	-5.54%	-13.43%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-11.48%	-7.08%	6.63%	-8.62%	-8.93%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-11.19%	-3.03%	2.36%	-4.77%	-21.75%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-12.09%	0.26%	2.69%	-1.54%	-19.01%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-13.31%	-5.28%	-8.18%	8.83%	-6.36%	-15.66%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-2.43%	80.97%	-144.75%	123.95%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-1.61%	-1.73%	-5,495.73%	-2.72%	-36.85%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	100.00%	95.53%	95.58%	73.71%	98.25%
EBITDA Margin	0.00%	0.00%	-658.30%	-5,714.54%	-767.35%	-521.57%	-6,272.23%	-258.95%
Operating Margin	0.00%	0.00%	-656.41%	-5,751.99%	-827.12%	-659.65%	-6,528.75%	-267.22%
EBIT Margin	0.00%	0.00%	-660.42%	-5,732.19%	-775.73%	-530.29%	-6,342.04%	-261.69%
Profit (Net Income) Margin	0.00%	0.00%	-711.50%	-6,127.87%	-841.20%	-624.17%	-7,021.94%	-244.86%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.21%
Interest Burden Percent	99.94%	90.15%	107.73%	106.90%	108.44%	117.70%	110.72%	93.37%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-44.90%	-67.64%	-173.15%	154.80%	45.93%	50.49%	38.81%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-48.85%	-70.82%	-63.02%	-50.34%	-100.91%	-79.24%
Return on Assets (ROA)	0.00%	0.00%	-52.63%	-75.71%	-68.34%	-59.25%	-111.72%	-74.14%
Return on Common Equity (ROCE)	0.00%	-37.47%	-57.33%	-138.31%	166.00%	46.24%	50.91%	39.11%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-53.81%	-70.65%	-872.95%	67.38%	38.63%	48.24%	37.02%
Net Operating Profit after Tax (NOPAT)	-31	-129	-186	-332	-404	-359	-425	-415
NOPAT Margin	0.00%	0.00%	-459.49%	-4,026.40%	-578.98%	-461.75%	-4,570.13%	-187.06%
Net Nonoperating Expense Percent (NNEP)	0.00%	-20.51%	-23.13%	-34.72%	-39.77%	-52.01%	-543.39%	-65.32%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	44.14%	47.42%	40.68%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	4.47%	4.42%	26.29%	1.75%
SG&A Expenses to Revenue	0.00%	0.00%	232.63%	1,766.08%	275.70%	184.41%	1,618.73%	130.21%
R&D to Revenue	0.00%	0.00%	517.62%	4,085.91%	646.94%	514.45%	4,898.54%	228.24%
Operating Expenses to Revenue	0.00%	0.00%	756.41%	5,851.99%	922.65%	755.22%	6,602.46%	365.48%
Earnings before Interest and Taxes (EBIT)	-44	-188	-268	-473	-541	-412	-590	-581
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-44	-188	-267	-471	-535	-405	-584	-575
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.11	10.60	150.52	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	1.11	10.60	150.52	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	106.79	1,056.59	35.21	14.67	754.92	23.37
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	96.49	1,000.44	29.46	13.78	755.64	21.67
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	129.31	4.44	0.00	0.00	58.26
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.14	0.19	0.87	-0.50	-0.35	-0.33	-0.30
Long-Term Debt to Equity	0.00	0.14	0.19	0.86	-0.50	-0.35	-0.33	-0.30
Financial Leverage	0.00	-1.06	-1.04	-1.71	1.21	0.23	0.03	0.14
Leverage Ratio	0.00	1.23	1.29	2.29	-2.27	-0.78	-0.45	-0.52
Compound Leverage Factor	0.00	1.11	1.38	2.44	-2.46	-0.91	-0.50	-0.49
Debt to Total Capital	0.00%	12.62%	16.17%	46.53%	-99.06%	-52.95%	-49.82%	-42.86%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.72%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	12.62%	16.17%	45.81%	-99.06%	-52.95%	-49.82%	-42.86%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	14.47%	11.89%	24.77%	-1.11%	-1.19%	-1.31%	-1.01%
Common Equity to Total Capital	0.00%	72.91%	71.94%	28.70%	200.17%	154.14%	151.13%	143.87%
Debt to EBITDA	0.00	-0.29	-0.34	-0.20	-0.81	-1.06	-0.77	-0.76
Net Debt to EBITDA	0.00	2.12	1.82	1.09	0.76	0.19	0.01	0.67
Long-Term Debt to EBITDA	0.00	-0.29	-0.34	-0.20	-0.81	-1.06	-0.77	-0.76
Debt to NOPAT	0.00	-0.42	-0.49	-0.28	-1.07	-1.20	-1.05	-1.05
Net Debt to NOPAT	0.00	3.10	2.60	1.55	1.01	0.22	0.01	0.93
Long-Term Debt to NOPAT	0.00	-0.42	-0.49	-0.28	-1.07	-1.20	-1.05	-1.05
Altman Z-Score	0.00	1.58	15.35	5.74	-2.00	-5.18	-7.14	-4.51
Noncontrolling Interest Sharing Ratio	0.00%	16.56%	15.23%	20.13%	-7.23%	-0.69%	-0.83%	-0.79%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	13.67	9.42	6.72	6.58	4.52	3.32	4.67
Quick Ratio	0.00	13.39	9.09	6.35	6.34	4.03	3.04	4.44
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-107	-198	64	463	-306	-401	83
Operating Cash Flow to CapEx	-8,725.86%	-6,273.78%	-9,612.85%	-5,316.76%	-3,759.13%	0.00%	-40,407.35%	-55,812.00%
Free Cash Flow to Firm to Interest Expense	0.00	-42.13	-22.62	1.74	9.89	-3.81	-4.94	0.66
Operating Cash Flow to Interest Expense	-3,114.46	-53.65	-28.93	-10.90	-10.64	-5.22	-6.49	-4.14
Operating Cash Flow Less CapEx to Interest Expense	-3,150.15	-54.50	-29.23	-11.11	-10.93	-5.15	-6.51	-4.14
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.07	0.01	0.08	0.09	0.02	0.30
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	68.56
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	11.27	0.64	2.77	3.48	0.71	23.57
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.30	0.29	0.22	0.38
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.32
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	1,220.71	1,245.83	1,657.35	954.05
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	-1,220.71	-1,245.83	-1,657.35	-948.73
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	-21	-9.37	-405	-1,272	-1,324	-1,348	-1,845
Invested Capital Turnover	0.00	0.00	-2.65	-0.04	-0.08	-0.06	-0.01	-0.14
Increase / (Decrease) in Invested Capital	0.00	-21	12	-396	-866	-52	-24	-498
Enterprise Value (EV)	0.00	12	3,913	8,253	2,053	1,070	7,030	4,809
Market Capitalization	349	349	4,331	8,716	2,455	1,139	7,023	5,186
Book Value per Share	$0.00	$5.10	$3.31	$0.47	($5.91)	($8.39)	($7.78)	($7.77)
Tangible Book Value per Share	$0.00	$5.10	$3.31	$0.47	($6.22)	($8.59)	($7.94)	($7.89)
Total Capital	0.00	432	568	202	-435	-814	-896	-1,020
Total Debt	0.00	55	92	94	431	431	446	437
Total Long-Term Debt	0.00	55	92	92	431	431	446	437
Net Debt	0.00	-399	-485	-513	-406	-79	-5.09	-388
Capital Expenditures (CapEx)	0.46	2.18	2.64	7.52	13	-5.18	1.31	0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-23	-38	-58	-83	-82	-118	-115
Debt-free Net Working Capital (DFNWC)	0.00	413	508	549	754	427	334	566
Net Working Capital (NWC)	0.00	413	508	547	754	427	334	566
Net Nonoperating Expense (NNE)	13	41	102	173	183	126	228	128
Net Nonoperating Obligations (NNO)	0.00	-399	-485	-513	-406	-79	-5.09	-388
Total Depreciation and Amortization (D&A)	0.00	0.00	0.86	1.46	5.84	6.77	6.49	6.08
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-93.09%	-708.68%	-119.13%	-106.15%	-1,266.13%	-51.80%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	1,253.05%	6,650.92%	1,081.23%	550.46%	3,587.54%	255.20%
Net Working Capital to Revenue	0.00%	0.00%	1,253.05%	6,633.24%	1,081.23%	550.46%	3,587.54%	255.20%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($2.48)	($3.80)	($3.90)	($3.26)	($3.95)	($2.88)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	123.77M	148.96M	147.61M	147.47M	162.79M	186.08M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($2.48)	($3.80)	($3.90)	($3.26)	($3.95)	($2.88)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	123.77M	148.96M	147.61M	147.47M	162.79M	186.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($2.48)	($3.80)	($3.90)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	105.10M	118.00M	144.36M	151.37M	175.83M	190.19M
Normalized Net Operating Profit after Tax (NOPAT)	-31	-129	-186	-332	-404	-328	-420	-404
Normalized NOPAT Margin	0.00%	0.00%	-459.49%	-4,026.40%	-578.98%	-422.30%	-4,510.49%	-182.13%
Pre Tax Income Margin	0.00%	0.00%	-711.50%	-6,127.87%	-841.20%	-624.17%	-7,021.94%	-244.34%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3,373.69	-73.80	-30.56	-12.90	-11.56	-5.12	-7.26	-4.61
NOPAT to Interest Expense	-2,361.58	-50.48	-21.26	-9.06	-8.63	-4.46	-5.23	-3.30
EBIT Less CapEx to Interest Expense	-3,409.38	-74.65	-30.86	-13.11	-11.84	-5.05	-7.27	-4.62
NOPAT Less CapEx to Interest Expense	-2,397.28	-51.33	-21.56	-9.27	-8.91	-4.39	-5.25	-3.30
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-2.63%	-26.10%	-19.06%	-0.99%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.63%	-26.10%	-19.06%	-15.83%	-34.10%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-85.58%	-85.49%	7.79%	-97.77%	1,110.36%	-6.68%	11,461.88%	32.11%	-33.22%	237.08%
EBITDA Growth	19.20%	9.42%	30.24%	-871.40%	-33.18%	-25.23%	109.13%	-22.11%	-16.78%	-44.78%
EBIT Growth	18.24%	9.22%	30.06%	-953.03%	-32.73%	-24.84%	107.75%	-21.81%	-16.55%	-44.18%
NOPAT Growth	13.63%	21.97%	27.36%	-82.22%	-22.13%	-37.28%	100.27%	-20.15%	-21.60%	-27.40%
Net Income Growth	12.93%	7.69%	29.11%	-6,179.91%	-28.03%	-21.17%	74.67%	52.99%	8.49%	-56.98%
EPS Growth	12.26%	9.00%	31.85%	-1,300.00%	-16.13%	-6.59%	78.26%	60.20%	20.37%	-47.42%
Operating Cash Flow Growth	-11.19%	30.36%	10.16%	-272.22%	-7.45%	-33.86%	-52.12%	165.90%	-24.33%	-56.49%
Free Cash Flow Firm Growth	-276.39%	-105.11%	48.50%	190.93%	189.45%	-161.69%	-141.29%	-107.24%	-108.30%	438.23%
Invested Capital Growth	98.11%	-4.10%	-1.32%	-3,397.34%	-5,445.64%	-1.80%	13.34%	-2.89%	-2.78%	-36.93%
Revenue Q/Q Growth	-99.54%	453.25%	-2.35%	-10.13%	149.30%	-57.35%	11,998.57%	-98.97%	26.01%	115.30%
EBITDA Q/Q Growth	-753.54%	-1.55%	-1.72%	-14.27%	-12.83%	4.51%	107.41%	-1,628.60%	-7.91%	-18.37%
EBIT Q/Q Growth	-824.22%	-1.54%	-1.68%	-14.09%	-12.69%	4.50%	106.31%	-1,892.91%	-7.82%	-18.14%
NOPAT Q/Q Growth	-61.04%	-0.09%	2.37%	-15.80%	-7.94%	-12.51%	100.19%	-51,277.55%	-9.24%	-17.88%
Net Income Q/Q Growth	-5,378.43%	-0.27%	-1.54%	-12.59%	-11.69%	5.10%	78.77%	-108.92%	-117.43%	-62.79%
EPS Q/Q Growth	-1,228.57%	2.15%	-1.10%	-6.52%	-10.20%	10.19%	79.38%	-95.00%	-120.51%	-66.28%
Operating Cash Flow Q/Q Growth	-343.84%	31.01%	-54.78%	21.46%	-28.12%	14.05%	-75.88%	134.03%	-341.71%	-8.17%
Free Cash Flow Firm Q/Q Growth	-2.07%	97.09%	-86.38%	1,741.37%	0.41%	-108.52%	-71.85%	50.76%	-15.19%	447.01%
Invested Capital Q/Q Growth	36.98%	-5,495.73%	2.20%	-1.41%	0.07%	-2.72%	16.75%	-20.40%	0.18%	-36.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	-118.64%	-6.68%	64.35%	63.50%	85.38%	65.73%	99.72%	72.42%	78.11%	64.57%
EBITDA Margin	-35,840.24%	-6,578.18%	-6,852.74%	-8,713.35%	-3,943.68%	-8,828.25%	5.41%	-8,053.37%	-6,896.60%	-3,791.84%
Operating Margin	-38,200.00%	-6,910.80%	-6,909.26%	-8,903.05%	-3,854.61%	-10,167.11%	0.16%	-8,096.82%	-7,018.67%	-3,842.69%
EBIT Margin	-36,326.92%	-6,666.95%	-6,942.17%	-8,813.10%	-3,983.74%	-8,919.08%	4.65%	-8,125.97%	-6,952.89%	-3,815.08%
Profit (Net Income) Margin	-41,477.22%	-7,517.11%	-7,816.65%	-9,792.99%	-4,387.39%	-9,760.92%	-17.13%	-3,484.50%	-6,012.23%	-4,545.89%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.43%
Interest Burden Percent	114.18%	112.75%	112.60%	111.12%	110.13%	109.44%	-368.00%	42.88%	86.47%	118.64%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	53.19%	45.93%	37.80%	49.41%	53.65%	50.49%	48.58%	37.96%	37.00%	38.81%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-4,265.33%	-632.92%	-750.56%	-73.23%	-54.29%	-141.91%	1.38%	-2,743.52%	-2,294.11%	-1,155.17%
Return on Assets (ROA)	-4,870.06%	-713.63%	-845.10%	-81.38%	-59.79%	-155.30%	-5.08%	-1,176.45%	-1,983.74%	-1,376.45%
Return on Common Equity (ROCE)	53.64%	46.24%	38.01%	49.89%	54.16%	50.91%	49.12%	38.32%	37.39%	39.11%
Return on Equity Simple (ROE_SIMPLE)	43.60%	0.00%	34.76%	42.89%	51.63%	0.00%	52.09%	42.23%	36.29%	0.00%
Net Operating Profit after Tax (NOPAT)	-90	-90	-88	-102	-110	-124	0.24	-123	-134	-158
NOPAT Margin	-26,740.00%	-4,837.56%	-4,836.48%	-6,232.13%	-2,698.23%	-7,116.97%	0.11%	-5,667.77%	-4,913.07%	-2,689.88%
Net Nonoperating Expense Percent (NNEP)	16.81%	-20.67%	-34.21%	11.52%	13.98%	-109.91%	-43.82%	40.81%	-24.20%	-55.60%
Return On Investment Capital (ROIC_SIMPLE)	-	11.14%	-	-	-	13.85%	-	-	-	15.51%
Cost of Revenue to Revenue	218.64%	106.68%	35.65%	36.50%	14.62%	34.27%	0.28%	27.58%	21.89%	35.43%
SG&A Expenses to Revenue	9,227.22%	1,703.85%	1,703.61%	2,201.22%	874.53%	2,726.82%	31.17%	2,745.53%	2,519.00%	1,611.39%
R&D to Revenue	27,370.12%	4,861.07%	5,085.49%	6,550.15%	3,058.81%	7,462.81%	66.77%	5,290.36%	4,408.64%	2,216.08%
Operating Expenses to Revenue	38,081.36%	6,976.20%	6,973.60%	8,966.54%	3,939.99%	10,232.84%	99.55%	8,169.23%	7,096.78%	3,907.26%
Earnings before Interest and Taxes (EBIT)	-123	-125	-127	-145	-163	-156	9.83	-176	-190	-224
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-121	-123	-125	-143	-161	-154	11	-175	-188	-223
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	16.62	14.67	32.27	486.45	454.43	754.92	24.61	21.63	21.98	23.37
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	29.19	13.78	31.38	495.11	443.36	755.64	24.28	20.45	21.44	21.67
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	3.11	4.66	0.00	0.00	0.00	0.00	58.26
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.50	-0.35	-0.36	-0.33	-0.37	-0.33	-0.42	-0.40	-0.36	-0.30
Long-Term Debt to Equity	-1.50	-0.35	-0.36	-0.33	-0.37	-0.33	-0.42	-0.40	-0.36	-0.30
Financial Leverage	-0.32	0.23	0.14	-0.43	-0.43	0.03	0.07	0.10	0.10	0.14
Leverage Ratio	-0.81	-0.78	-0.64	-0.58	-0.60	-0.45	-0.66	-0.53	-0.55	-0.52
Compound Leverage Factor	-0.92	-0.87	-0.72	-0.64	-0.66	-0.49	2.41	-0.23	-0.47	-0.62
Debt to Total Capital	298.90%	-52.95%	-56.02%	-48.45%	-58.74%	-49.82%	-72.20%	-67.34%	-55.77%	-42.86%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	298.90%	-52.95%	-56.02%	-48.45%	-58.74%	-49.82%	-72.20%	-67.34%	-55.77%	-42.86%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.42%	-1.19%	-1.55%	-1.36%	-1.84%	-1.31%	-2.10%	-1.68%	-1.47%	-1.01%
Common Equity to Total Capital	-200.31%	154.14%	157.57%	149.81%	160.57%	151.13%	174.30%	169.01%	157.24%	143.87%
Debt to EBITDA	-4.07	-1.06	-1.24	-0.86	-0.80	-0.77	-0.97	-0.91	-0.86	-0.76
Net Debt to EBITDA	-2.65	0.19	0.23	-0.07	0.21	0.01	0.19	0.56	0.26	0.67
Long-Term Debt to EBITDA	-4.07	-1.06	-1.24	-0.86	-0.80	-0.77	-0.97	-0.91	-0.86	-0.76
Debt to NOPAT	-4.42	-1.20	-1.34	-1.19	-1.13	-1.05	-1.29	-1.22	-1.14	-1.05
Net Debt to NOPAT	-2.88	0.22	0.25	-0.10	0.30	0.01	0.25	0.75	0.34	0.93
Long-Term Debt to NOPAT	-4.42	-1.20	-1.34	-1.19	-1.13	-1.05	-1.29	-1.22	-1.14	-1.05
Altman Z-Score	-2.52	-3.66	-3.45	-5.43	-3.65	-4.52	-1.37	-2.92	-4.50	-3.23
Noncontrolling Interest Sharing Ratio	-0.83%	-0.69%	-0.55%	-0.97%	-0.94%	-0.83%	-1.10%	-0.95%	-1.05%	-0.79%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.39	4.52	5.72	3.93	5.54	3.32	5.54	4.59	3.19	4.67
Quick Ratio	5.17	4.03	5.20	3.56	5.17	3.04	5.34	3.34	1.92	4.44
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,317	-38	-71	1,173	1,178	-100	-172	-85	-98	339
Operating Cash Flow to CapEx	-17,808.04%	-11,640.82%	-1,202,683.33%	-26,484.35%	-33,695.13%	-28,694.02%	-31,588.06%	138,338.89%	-131,800.00%	-415,587.23%
Free Cash Flow to Firm to Interest Expense	-66.42	-1.92	-3.55	56.96	58.01	-4.95	-3.44	-3.70	-4.24	11.38
Operating Cash Flow to Interest Expense	-6.82	-4.66	-7.17	-5.50	-7.15	-6.16	-4.39	3.26	-7.83	-6.55
Operating Cash Flow Less CapEx to Interest Expense	-6.86	-4.70	-7.17	-5.53	-7.17	-6.18	-4.40	3.25	-7.84	-6.55
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.12	0.09	0.11	0.01	0.01	0.02	0.30	0.34	0.33	0.30
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	68.56
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.09	3.48	5.06	0.38	0.67	0.71	17.50	19.15	20.63	23.57
Accounts Payable Turnover	0.41	0.29	0.58	0.63	0.53	0.22	0.54	0.22	0.27	0.38
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.32
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	889.57	1,245.83	633.63	580.25	694.76	1,657.35	671.43	1,678.51	1,360.74	954.05
Cash Conversion Cycle (CCC)	-889.57	-1,245.83	-633.63	-580.25	-694.76	-1,657.35	-671.43	-1,678.51	-1,360.74	-948.73
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-24	-1,324	-1,295	-1,313	-1,312	-1,348	-1,122	-1,351	-1,348	-1,845
Invested Capital Turnover	-0.14	-0.06	-0.06	-0.01	-0.01	-0.01	-0.18	-0.16	-0.16	-0.14
Increase / (Decrease) in Invested Capital	1,226	-52	-17	-1,275	-1,288	-24	173	-38	-36	-498
Enterprise Value (EV)	2,588	1,070	2,441	2,810	4,180	7,030	5,307	4,482	4,669	4,809
Market Capitalization	1,474	1,139	2,510	2,761	4,284	7,023	5,379	4,740	4,787	5,186
Book Value per Share	($7.68)	($8.39)	($8.10)	($8.49)	($7.43)	($7.78)	($5.87)	($5.84)	($6.54)	($7.77)
Tangible Book Value per Share	($7.88)	($8.59)	($8.28)	($8.66)	($7.60)	($7.94)	($6.02)	($5.97)	($6.67)	($7.89)
Total Capital	568	-814	-778	-909	-752	-896	-602	-647	-782	-1,020
Total Debt	1,699	431	436	440	442	446	435	435	436	437
Total Long-Term Debt	1,699	431	436	440	442	446	435	435	436	437
Net Debt	1,107	-79	-81	37	-118	-5.09	-85	-269	-130	-388
Capital Expenditures (CapEx)	0.76	0.80	0.01	0.43	0.43	0.44	0.70	0.05	0.14	0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-69	-82	-61	-81	-78	-118	122	-105	-100	-115
Debt-free Net Working Capital (DFNWC)	523	427	456	323	482	334	642	482	305	566
Net Working Capital (NWC)	523	427	456	323	482	334	642	482	305	566
Net Nonoperating Expense (NNE)	50	50	54	58	69	46	36	-47	30	109
Net Nonoperating Obligations (NNO)	1,107	-79	-81	37	-118	-5.09	-85	-269	-130	-388
Total Depreciation and Amortization (D&A)	1.65	1.66	1.63	1.64	1.64	1.59	1.60	1.57	1.54	1.37
Debt-free, Cash-free Net Working Capital to Revenue	-77.77%	-106.15%	-78.03%	-1,426.61%	-830.63%	-1,266.13%	55.87%	-48.06%	-46.09%	-51.80%
Debt-free Net Working Capital to Revenue	589.90%	550.46%	586.41%	5,687.47%	5,108.24%	3,587.54%	293.67%	219.91%	140.23%	255.20%
Net Working Capital to Revenue	589.90%	550.46%	586.41%	5,687.47%	5,108.24%	3,587.54%	293.67%	219.91%	140.23%	255.20%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.93)	($0.91)	($0.92)	($0.98)	($1.08)	($0.97)	($0.20)	($0.39)	($0.86)	($1.43)
Adjusted Weighted Average Basic Shares Outstanding	147.94M	147.47M	152.65M	160.54M	163.31M	162.79M	178.71M	187.59M	188.51M	186.08M
Adjusted Diluted Earnings per Share	($0.93)	($0.91)	($0.92)	($0.98)	($1.08)	($0.97)	($0.20)	($0.39)	($0.86)	($1.43)
Adjusted Weighted Average Diluted Shares Outstanding	147.94M	147.47M	152.65M	160.54M	163.31M	162.79M	178.71M	187.59M	188.51M	186.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	149.48M	151.37M	160.50M	162.47M	173.97M	175.83M	187.13M	188.03M	188.99M	190.19M
Normalized Net Operating Profit after Tax (NOPAT)	-87	-85	-86	-100	-110	-124	2.62	-121	-131	-155
Normalized NOPAT Margin	-25,701.18%	-4,549.66%	-4,707.33%	-6,081.51%	-2,693.57%	-7,086.73%	1.24%	-5,574.43%	-4,794.67%	-2,634.03%
Pre Tax Income Margin	-41,477.22%	-7,517.11%	-7,816.65%	-9,792.99%	-4,387.39%	-9,760.92%	-17.13%	-3,484.50%	-6,012.23%	-4,526.28%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-6.19	-6.24	-6.30	-7.02	-8.03	-7.68	0.20	-7.68	-8.24	-7.53
NOPAT to Interest Expense	-4.56	-4.53	-4.39	-4.97	-5.44	-6.13	0.00	-5.36	-5.82	-5.31
EBIT Less CapEx to Interest Expense	-6.23	-6.28	-6.30	-7.04	-8.05	-7.70	0.18	-7.68	-8.24	-7.53
NOPAT Less CapEx to Interest Expense	-4.60	-4.57	-4.39	-4.99	-5.46	-6.15	-0.01	-5.36	-5.83	-5.31
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About BridgeBio Pharma's Financials

When does BridgeBio Pharma's financial year end?

According to the most recent income statement we have on file, BridgeBio Pharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has BridgeBio Pharma's net income changed over the last 7 years?

BridgeBio Pharma's net income appears to be on an upward trend, with a most recent value of -$543.35 million in 2024, rising from -$43.83 million in 2017. The previous period was -$653.25 million in 2023.

What is BridgeBio Pharma's operating income?

BridgeBio Pharma's total operating income in 2024 was -$592.97 million, based on the following breakdown:

Total Gross Profit: $218.02 million
Total Operating Expenses: $811.00 million

How has BridgeBio Pharma revenue changed over the last 7 years?

Over the last 7 years, BridgeBio Pharma's total revenue changed from $0.00 in 2017 to $221.90 million in 2024, a change of 22,190,200,000.0%.

How much debt does BridgeBio Pharma have?

BridgeBio Pharma's total liabilities were at $2.38 billion at the end of 2024, a 25.8% increase from 2023, and a 2,614.1% increase since 2018.

How much cash does BridgeBio Pharma have?

In the past 6 years, BridgeBio Pharma's cash and equivalents has ranged from $356.08 million in 2020 to $681.10 million in 2024, and is currently $681.10 million as of their latest financial filing in 2024.

How has BridgeBio Pharma's book value per share changed over the last 7 years?

Over the last 7 years, BridgeBio Pharma's book value per share changed from 0.00 in 2017 to -7.77 in 2024, a change of -776.7%.

Remove Ads

Related Companies

This page (NASDAQ:BBIO) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Financials

Frequently Asked Questions About BridgeBio Pharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Financials

Annual Income Statements for BridgeBio Pharma

Quarterly Income Statements for BridgeBio Pharma

Annual Cash Flow Statements for BridgeBio Pharma

Quarterly Cash Flow Statements for BridgeBio Pharma

Annual Balance Sheets for BridgeBio Pharma

Quarterly Balance Sheets for BridgeBio Pharma

Annual Metrics and Ratios for BridgeBio Pharma

Quarterly Metrics and Ratios for BridgeBio Pharma

Frequently Asked Questions About BridgeBio Pharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools